Reprogramming somatic cells into a pluripotent state brings patient-tailored, ethical controversy-free cellular therapy closer to reality. However, stem cells and cancer cells share many common characteristics; therefore, it is crucial to be able to discriminate between them. We generated two induced pluripotent stem cell (iPSC) lines, with NANOG pre-transduction followed by OCT3/4, SOX2, and LIN28 overexpression. One of the cell lines, CHiPS W, showed normal pluripotent stem cell characteristics, while the other, CHiPS A, though expressing pluripotency markers, failed to differentiate and gave rise to germ cell-like tumours in vivo. Comparative genomic hybridisation analysis of the generated iPS lines revealed that they were genetically more stable than human embryonic stem cell counterparts. This analysis proved to be predictive for the differentiation potential of analysed cells. Moreover, the CHiPS A line expressed a lower ratio of p53/p21 when compared to CHiPS W. NANOG pre-induction followed by OCT3/4, SOX2, MYC, and KLF4 induction resulted in the same tumour-inducing phenotype. These results underline the importance of a re-examination of the role of NANOG during reprogramming. Moreover, this reprogramming method may provide insights into primordial cell tumour formation and cancer stem cell transformation.
Introduction
Pluripotent stem cells have attracted much attention from the scientifi c community in recent years. They hold promise for various therapeutic applications, from regenerative therapies to pharmacological screening.
Technical diffi culties and ethical issues associated with the isolation of adult or embryonic stem cells have redirected interest towards induced pluripotent stem cells (iPSCs).
Obtained from lineage-specifi c cells via reprogramming with a maximum of four reprogramming genes (RGs), POU5F1 (OCT3/4), SOX2 and MYC, KLF4, or NANOG and LIN28 (Takahashi et al., 2007; Yu et al., 2007) , iPSCs seem to be a very promising area for future stem cell research. Despite obvious advantages such as donor compatibility and an unlimited supply, there are still numerous challenges to be met before iPSCs become routinely used in regenerative medicine or standardised for patient-specifi c drug research (reviewed in: Stadtfeld and Hochedlinger, 2010) . One major obstacle is the capability of pluripotent stem cells to form tumours in vivo. At fi rst, human embryonic stem cells (hESC) were believed to produce only benign teratomas; however, recent studies have demonstrated that hESC lines can also develop malignant features after being kept in culture reviewed in: Blum and Benvenisty, 2009) .
There is increasing evidence of the existence of a distinct cell sub-population within a tumour, called cancer stem cells (CSCs), which shares many characteristics with normal stem cells (Bonnet and Dick, 1997) . CSCs are believed to be responsible for the tumour's ability to undergo epithelial-mesenchymal transition (EMT), and may play a role in relapse, metastasis, and treatment resistance (reviewed in: Bomken et al., 2010; Tysnes, 2010) . It remains controversial as to whether CSCs originate from stem cells that have undergone aberrant transformation or from terminally differentiated cells that have reversed their cellular program. Very limited evidence indicates that normal stem cells and cancer stem cells differ (Guzman et al., 2005; Yilmaz et al., 2006) . Therefore, it is crucial to understand the carcinogenic aspect of stem cells before they can be implemented I Grad et al. NANOG priming may generate germ cell tumours therapeutically. Thus, research towards fi nding ways to limit the tumour formation risk of iPSC, for instance by developing strategies allowing accurate sorting of potentially carcinogenic cells, is essential. In the present study, we generated and analysed two iPSC lines. One of the lines, the CHiPS W, displayed normal pluripotent stem cell characteristics and gave rise to a teratoma expressing components of the three germ layers during an in vivo differentiation assay. The other line, the CHiPS A, despite its iPSC-like morphology and marker expression, resulted in germ cell-like tumours when injected into immunoincompetent mice. The analysis of OCT3/4 and NANOG expression and the methylation status of their promoters showed their re-activation in the CHiPS A line. Since it has been previously demonstrated that genomic instability in hESC lines might lead to neoplastic progression (Werbowetski-Ogilvie et al., 2009) , we used comparative genomic hybridisation and single nucleotide polymorphism assays to detect genomic signatures in the derived iPSC lines. We also estimated the relative expression of TP53 (p53) and CDKN1A (p21) in both lines. Finally, we showed that the resulting NANOG-induced tumourigenic phenotype is independent of the other RGs used. These results underline the importance of a reexamination of the role of NANOG during reprogramming and the need for detailed iPSC characterisation prior to clinical use. Moreover, as the generated lines were derived from a uniform genetic background, they may serve as a model of cancer stem cell formation.
Materials and Methods

Cell lines
The hESC line H1 came from the WiCell Research Institute (Madison, WI, USA). HS401 was derived as previously described (Inzunza et al. 2005; Ström et al., 2010) . iPSC lines were derived as follows: the CHiPS A line was derived by transducing 50,000 human fi broblasts (ATCC, CRL-2429) with 5 MOI of pSin-EF2-Nanog-Pur. After 24 h, cells were re-transduced with three viruses (MOI 5): pSin-EF2-Sox2-Pur, pSin-EF2-Oct4-Pur, and pSin-EF2-Lin28-Pur (kindly donated by J.A. Thomson). The CHiPS W line was derived by transducing 50,000 human fi broblasts with 5 MOI of pSin-EF2-Nanog-Pur. The cells were treated with puromycin for 5 days to select for transformed cells and then re-transduced with three viruses: pSin-EF2-Sox2-Pur, pSin-EF2-Oct4-Pur, and pSin-EF2-Lin28-Pur (MOI 5). The CHiPS 22 line was derived by fi rst transducing 50,000 human fi broblasts with 5 MOI of pSin-EF2-Nanog-Pur; after 24 h, cells were re-transduced with the Stem Cell Cassette (STEMCCA) polycistronic lentiviral vector, carrying the four Yamanaka RGs (Sommer et al., 2009) (kindly donated by G. Mostoslavsky). All iPSC and hESC lines were cultured on irradiated human foreskin fi broblasts and passaged mechanically. Cells were grown in iPSC medium: Knockout Dulbecco's Minimal Essential Medium (DMEM) supplemented with 20 % Serum Replacement, 2 mmol/L Glutamax, 40 μg/mL gentamycin and 100 μmol/L β-mercaptoethanol (all Gibco/Invitrogen, Carlsbad, CA, USA). For the H1 cell line, medium was supplemented with 10 ng/mL bFGF (fi broblast growth factor). All iPSC lines were initially cultured according to the protocol established by Thomson's group , and supplemented with 100 ng/mL bFGF; however, the CHiPS 22 and CHiPS A lines grew robustly, so we decided to lower the concentration of bFGF to 10 ng/mL for those lines to decrease the cost of culture. 
Immunohistochemistry
Cells were passaged manually onto a GFP-positive feeder layer (Unger et al., 2009) . After fixation in 4 % formaldehyde, they were washed three times with phosphate buffered saline (PBS), blocked with 1 % bovine serum albumin (BSA) and stained with antibodies against OCT3/4 (Santa Cruz Laboratories, Santa Cruz, CA, USA; sc-5279), NANOG (Santa Cruz Laboratories, sc-33759), TRA-1-60 (Santa Cruz Laboratories, sc-21705), and SSEA4 (Santa Cruz Laboratories, sc-21704) overnight at 4 °C. After three washes with PBS, cells were incubated with fl uorescent probe-labelled secondary antibodies and mounted with UltraCruz™ Mounting Medium containing DAPI. Ki-67 immunostaining was performed as follows: after standard deparaffi nisation, antigen retrieval was performed with 0.01 M citrate (pH 6) at 100 °C. Endogenous peroxidase was blocked with HP-Blocking solution (S2023; Dako, Glostrup, Denmark) and the slides were incubated with a Ki-67 antibody (mib1, Dako, M7240). Secondary antibody incubation and signal development was performed in DAB solution according to the manufacturer's instruction (Dako). All staining were performed three times independently.
Karyotype
Karyotyping was performed in at least twenty metaphase spreads, using the GTG-banding method, by an independent laboratory (Genetic Service, Geneva University Hospitals, Switzerland). Briefly, iPSCs were incubated in iPSC medium, supplemented with 0.2 mg/mL colcemid (Roche, Basel, Switzerland) at 37 °C for 20 min, and subsequently washed three times with 2 mL PBS containing Ca 2+ and Mg
2+
. A minimum of 15 colonies were collected in 2 mL 1× trypsin-EDTA (Invitrogen) and incubated at 37 °C for 5 min. The fi nal mixture of cells was pipetted several times to disaggregate the cells. The trypsin activity was stopped with 4 mL iPSC medium and cells were spun at 300 g www.ecmjournal.org I Grad et al. NANOG priming may generate germ cell tumours for 10 min. Subsequently, the pellet was resuspended and incubated in 1 mL pre-warmed potassium chloride solution (KCl, 0.075 M) for 10 min at 37 °C. Cells were then prefi xed with 1 mL Carnoy fi xative solution (methanol/acetic acid = 3/1) at -20 °C, and immediately spun at 1800 rpm for 10 min. Finally, the supernatant was discarded, the pellet resuspended again in Carnoy fi xative solution and the cells were prepared for analysis.
RNA extraction, quantitative and non-quantitative real time polymerase chain reaction Total RNA was extracted from the cell lines, using the QIAGEN (Hilden, Germany) RNeasy MiniKit according to the manufacturer's protocol (Invitrogen). RNA integrity and quantity were assessed with an Agilent (Santa Clara, CA, USA) 2100 bioanalyser, using RNA 6000 nanochips. Table 1 . Primers used in the study.
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Time PCR (DART-PCR) algorithm, as described (Peirson et al., 2003) . A mean quantity was calculated from triplicate PCR reactions for each sample, and this quantity was normalised to similarly measured quantity of normalisation gene (GusB). The highest normalised relative quantity was arbitrarily designated as a value of 1.0 and the other quantities were recalculated proportionally. Each PCR reaction was performed at least in triplicate with negative controls and the mean quantities were calculated from them. They were expressed as +/-SD. For non-quantitative PCR, reactions were performed in a Biometra (Göttingen, Germany) thermocycler, with RedTaq polymerase mix (Sigma-Aldrich, St. Louis, MO, USA), 250 nM primers and 1 μL of cDNA. In the case of teratoma RT-PCR, we used 3 μL of template cDNA. Primers are listed in Table 1 .
Bisulphite sequencing
About 2 μg of DNA, extracted from the iPSC and control cell lines, were bisulphite-converted and purifi ed using Epitect Bisulfite Kits (Qiagen) following the manufacturer's instructions. DNA bisulphite treatment and processing were performed simultaneously for all cell lines. The promoter regions of OCT4 and NANOG were amplifi ed with specifi c primers as described previously (Freberg et al., 2007) using JumpStart REDTaq DNA Polymerase (Sigma-Aldrich) and KAPA2G Robust DNA Polymerase (Kapa Biosystems, Cambridge, MA, USA). Unincorporated primers and nucleotides were removed by incubation with Exonuclease I and Shrimp Alkaline Phosphatase (New England Biolabs, Ipswich, MA, USA), and the PCR products were cloned into the pCRII-TOPO vector (Invitrogen); transformants were grown on agar plates supplemented with X-Gal. Randomly chosen clones containing an insert were re-amplifi ed by M13 primers and sequenced by SP6 and T7 common primers from each cell line for each gene.
Teratoma formation assay
IPS cells were grown on Matrigel-coated dishes and collected by trypsin digestion. About 5x10 6 cells mixed with Matrigel (diluted in KO DMEM 5:1) were injected into the hind limb muscle of 8-week-old Nod-SCID mice. Teratomas were dissected after 8-12 weeks and fi xed in 4 % paraformaldehyde overnight. Samples were embedded in paraffi n, cut, and stained with haematoxylin and eosin.
Affymetrix SNP 6.0 array and DNA copy number variations Genotyping was carried out using the Affymetrix GenomeWide Human SNP Array 6.0 (San Diego, CA, USA). Labelling and hybridisation were performed following the protocols and kits provided by the manufacturer (Affymetrix Genome-Wide Human SNP Nsp/Sty Assay Kit 5.0/6.0). A set of 50 arrays previously hybridised and genotyped in the same laboratory was used as the copy number neutral reference sample. Copy-number variations (CNVs) and loss of heterozygosity (LOHs) were extracted with the Affymetrix proprietary Genotyping Console Software, using the standard setup recommended by the producer. Variations were annotated using the libraries supplied by Affymetrix (version 29). Copy number neutral LOH regions (UPDs) were detected by determining LOH regions from the genotype calls (dChip, https://sites. google.com/site/dchipsoft/home, 2010) and by comparing the results with the ploidy detected in those regions by the Affymetrix software. Genes were annotated to detect variations using the Biomart database (http://www.biomart. org/, 2010). Gene ontology analysis was performed in R (www.r-project.org, 2010) using the package GO_stats ver. 2.12. The gene's universe was determined from the Affymetrix annotation fi les (version 29).
In vitro differentiation of the pluripotent stem cells Whole iPSC and hESC colonies were dissected into ultra low attachment dishes (Corning Costar, Lowell, MA, USA) in KO DMEM medium supplemented with 10 % NCS, 1 mM L-glutamine, 100 μM non-essential amino acids, 100 μM 2-mercaptoethanol, 50 U/mL penicillin and 50 mg/mL streptomycin (Gibco/Invitrogen). Within 24 h, cells aggregated to form embryoid bodies (EBs). Cardiac differentiation was performed using standard procedures, as previously described (Bettiol et al., 2006) . Haematopoietic differentiation was carried out as recently described (Chicha et al., 2011) . Briefly, collagenased colonies of iPSC were resuspended in StemPro-34 Serum-Free Media (Gibco/Invitrogen) supplemented with 0.5 ng/mL human recombinant BMP-4 (R&D Systems, Minneapolis, MN, USA) in low cluster tissue culture dishes (Corning Costar, Lowell, MA, USA). At day 1 of differentiation, embryoid bodies (EBs) were harvested and transferred to fresh StemPro media supplemented with 10 ng/mL BMP-4 and 5 ng/mL bFGF. After 72 h, EBs were harvested again and transferred to a haematopoietic medium consisting of StemPro media supplemented with 100 ng/mL human recombinant VEGF (R&D Systems), 5 ng/mL bFGF, 100 ng/mL SCF (Amgen), 100 ng/mL FLT3-L (Amgen), and 40 ng/mL TPO (Peprotech, London, UK) for 4 additional days. All differentiation steps were performed under hypoxic conditions (5 % O 2 ) in a humidifi ed incubator at 37 °C.
Flow cytometry
Cell suspensions were analysed after staining with antibodies specifi c for CD34 and KDR (BD Biosciences, Allschwill, Switzerland). Dead cells were identifi ed as 7-aminoactinomycin D (7AAD)-positive cells and were excluded. Cells were stained in PBS containing 20 % human AB serum (Sigma-Aldrich) to prevent nonspecifi c binding. Data were collected using a FACS Calibur device (BD Biosciences) and analysed with Flowjo software (Treestar, Olten, Switzerland).
Immunoblotting
CHiPS A and CHiPS W cells were grown on Matrigelcoated dishes, trypsinised and counted. Protein extracts were prepared by lysing the cells in protein isolation buffer (10 mM Tris-HCl pH 8, 1 % Triton-X100, 2 mM EDTA, 10 % glycerol, 137 mM NaCl, and a proteinase inhibitor cocktail) to a fi nal concentration of about 300,000 cells per 15 μL. The lysates from 300,000 cells were resolved by SDS-polyacrylamide gel electrophoresis. For immunoblotting, the following antibodies were used: a p53-specifi c polyclonal antibody (Santa Cruz Laboratories, I Grad et al. NANOG priming may generate germ cell tumours sc-126), and a monoclonal p21-specifi c antibody (Santa Cruz Laboratories, sc-397). The experiment was repeated three times independently.
Results
Generation and characterisation of iPS cells from human fi broblasts
It has been demonstrated that the introduction of four reprogramming factors (OCT3/4, SOX2, NANOG, and LIN28) into a somatic cell results in a return to the pluripotent state, albeit with low effi ciency (Takahashi et al., 2007; Yu et al., 2007) . Given that Nanog overexpression in mouse ESC increases reprogramming effi ciency (Silva et al., 2006) , and that re-induction of the reprogramming transgenes leads to higher iPSCs generation (Maherali et al., 2008) , we wanted to check whether two-step reprogramming would increase the effectiveness of the process. Therefore, human fi broblasts were reprogrammed to pluripotency fi rst by using only a NANOG-expressing lentiviral vector . After 24 h, one part of the cells were re-transduced with three separate lentiviral vectors overexpressing the transcription factors OCT3/4, SOX2, and LIN28 , resulting in the CHiPS A line (Fig. 1A) . The other part of the cells was treated with puromycin for 5 days before re-transduction with the same lentivectors as the CHiPS A line, resulting in the CHiPS W line (Fig. 1A) . After three weeks, reprogrammed colonies were manually selected based on morphological criteria and expanded. The selected clones had typical ESC morphology (Fig. 1B) and displayed a normal karyotype as assessed by metaphase spreads (Fig.  1C) ; however, the CHiPS A line proliferated signifi cantly Fig. 2A) . We analysed the expression of pluripotency markers ZFP42 (REX1), SOX2, NANOG, LIN28, and OCT3/4 by quantitative PCR (Fig.  2B) . The analysis showed that, contrary to the CHiPS W line, the CHiPS A line did not express SOX2 and REX1 but overexpressed OCT3/4 instead. In addition, the levels of LIN28 in the CHiPS A line were also higher than in the CHiPS W line. To clarify the origin of the transcript, we performed bisulphite sequencing, which revealed a surprising methylation status of the OCT3/4 and NANOG promoters in the CHiPS A and W lines (Fig. 2C) . Despite overexpression of OCT3/4, the OCT3/4 promoter in the CHiPS A line was highly (55 %) methylated, while the NANOG promoter was demethylated. CHiPS W showed negligible methylation at the OCT3/4 promoter and moderate methylation at the NANOG promoter (Fig.  2C) . The results suggest a lack of retroviral silencing and therefore exogenous expression of OCT3/4 in the CHiPS A line. Semi-quantitative RT-PCR confi rmed the predominant (Fig. 2D) . At the same time low levels of endogenous NANOG expression in CHiPS A line, despite complete promoter demethylation suggest other mechanisms blocking gene expression.
Differentiation potential of CHiPS A
The CHiPS A line, despite its ES-like morphology, failed to differentiate in vitro (Fig. 3A) . During differentiation via embryoid bodies (EBs), in contrast to the CHiPS W line and the control hESC H1 line, EBs of CHiPS A dissociated over time (Fig. 3A) . We also tried to direct differentiation of CHiPS A under adherent conditions using 10 μM all-trans retinoic acid or to induce differentiation on a Matrigel-coated dish by bFGF withdrawal. However, we were unable to obtain mature EBs and cells ultimately dissociated over time (data not shown). To investigate the differentiation commitment to the three embryonic germ layers, we analysed the acquired expression of FOXA2 (endoderm), MSI1 (ectoderm), and Brachyury (mesoderm) marker genes within the EBs of CHiPS A and CHiPS W from day 0 to day 8 (Fig. 3B) . We observed the expected change in all the markers analysed in the CHiPS W and hESC H1 lines, indicating proper differentiation commitment. However, none of the markers increased with time in the CHiPS A line (Fig. 3B) . We decided to verify whether this disability regarding in vitro differentiation extended into a defect in an in vivo teratoma formation assay. The histological examination showed that the CHiPS A cells formed invasive (multiple infi ltrations into the surrounding tissue, lack of defi ned borders) germ celllike tumours when injected into NOD-SCID mice (Fig.  3C ). In the same assay, the CHiPS W cells formed benign teratomas, as expected (Fig. 3C ). To confi rm the germ cell-like nature of the CHiPS A tumour, we also verifi ed the expression of known seminoma markers DAZL, GDF3, KIT, and STELLAR, as well as the pluripotency markers NANOG, OCT3/4, and SOX2 (Ezeh et al., 2005; Gopalan et al., 2009) (Fig. 3D) . We observed strong endogenous 
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and exogenous NANOG expression as well as GDF3 and STELLAR. DAZL and KIT were weakly expressed (Fig. 3D) . However, KIT gave a very strong signal in the immunohistochemical assessment of the CHIPS A-derived tumor (Fig. 4A) as well as CD99, a known marker of primitive neuroectodermal and sex cord stromal tumours (Fig. 4B ). In line with commonly increased proliferation in tumours (Soini et al., 1998) , the CHiPS A-derived tumours showed a higher proliferative index compared to the CHiPS W-and H1-derived teratomas (Fig. 4C ).
To investigate whether priming the cells with NANOG could have activated the carcinogenic program during reprogramming, regardless of the choice of other reprogramming genes, we repeated human fibroblast reprogramming, fi rst with NANOG and then with the set of four Yamanaka reprogramming factors (OCT3/4, SOX2, MYC, KLF4) expressed from one polycistronic vector (Sommer et al., 2009 ). The resulting iPSC line, the CHiPS 22, also failed to differentiate in vitro. Importantly, in the teratoma formation assay, the CHiPS 22 cells gave rise to germ cell-like tumours, as did the CHiPS A cells (Fig.  5A) . Semi-quantitative RT-PCR analysis of pluripotency gene expression showed that similarly to the CHiPS A line, transgenes for OCT3/4 and NANOG were not silenced, however, the relative quantities of the endogenous versus exogenous transcripts resembled those of the CHiPS W (Fig. 5B) . Similar to the CHiPS W and by contrast to the CHiPS A, the OCT3/4 promoter of the CHiPS 22 was found hypomethylated (Fig. 5C) . Therefore, we conclude that priming cells with NANOG before complete reprogramming might result in a germ cell-like tumour phenotype in vivo, regardless of the reprogramming factors used.
Molecular characterisation
It has been previously demonstrated that genomic abnormalities in hESC might lead to neoplastic progression (Werbowetski-Ogilvie et al., 2009). To investigate the NANOG priming may generate germ cell tumours origin of the oncogenic potential of the CHiPS A line, array comparative genomic hybridisation (aCGH) was performed to evaluate the presence of genomic signatures. We compared the CHiPS A and CHiPS W lines with four hESC lines. This revealed some chromosomal variations, which were not detected previously with G banding. Surprisingly, the total observed abnormalities were minor, compared to the ESC lines (Fig. 6A,B) . Detailed analysis of each chromosome showed that the gains and losses were mainly concentrated in chromosomes 1, 3, 14, 16, 21, 22, and X for CHiPS A and 3, 16, and X for CHiPS W (Fig. 6D ). There were also multiple uniparental disomies affecting chromosomes 1, 2, 4, 5, 6, 7, 8, 9, 10, 12 , and 18 in both lines in the same manner, suggesting a parental origin. Surprisingly, thorough examination revealed only a few genes present in the affected regions (Fig. 6C ). Of these, 26 differed between the CHiPS A and the CHiPS W lines, 10 in the deleted regions and 16 in duplicated regions (Fig. 6E ). Those genes were CHiPS A-specifi c, since they were also absent, apart from the olfactory receptor OR11H12, from the mutated regions of the control hESC line (HS401) ( Table 2) . Unexpectedly, the genes did not 
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include any tumour suppressor genes or oncogenes, nor did they encompass any known pluripotency genes ( Table  2) . The gene ontology analysis performed for three classes (Gene Ontology Molecular Function (GOMF), Biological Processes (GOBP) and Kegg pathways) showed multiple differences between the two lines, as summarised in Table  3 . Of particular interest were potential defects in the cardiac and haematopoietic differentiation pathways in the CHiPS A line, as also revealed in the comparative pathway analysis between the CHiPS A and HS401 lines (Table 4) . To evaluate the prognostic values of aCGH analysis, we investigated whether the cells were capable of cardiac and directed haematopoietic differentiation in vitro, via embryoid body formation. In line with the aCGH data, quantitative analysis of the expression of the TBX1/ Brachyury, a major regulator of cardiac mesoderm formation, and NKX2-5, a cardiopoietic marker, revealed their absence from the CHiPS A line during in vitro cardiac differentiation (Fig. 7A) . Further differentiation led to beating cardiomyocytes in case of the CHiPS W (Chicha et al., 2011) , but not in the CHiPS A, which failed to differentiate and dissociated over time. It has been previously shown that the CHiPS W line is capable of undergoing haematopoietic differentiation (Chicha et al., 2011) . FACS analysis of differentiating embryoid bodies from the CHiPS W and the hESC H1 line showed an increase in the CD34+/KDR+ cell population with differentiation time; however, these vascular endothelial surface antigen markers were absent from the CHiPS A line (Fig. 7B) .
The TP53 (p53) tumour suppressor is an established factor connecting tumourigenesis and reprogramming to pluripotency, (reviewed in Tapia and Scholer, 2010) . Therefore, we analysed p53 and p21 protein levels in the CHiPS A and CHiPS W cell lines. In the normal, pluripotent CHiPS W cell line, the proportion of p53 to p21 was higher than in the tumourigenic CHiPS A cell line (Fig. 7C) .
Discussion
Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) offer great therapeutic promise. However, their potential tumourigenicity must be addressed before they can be taken into the clinic. In 1997, Bonnet and Dick proposed the new concept of cancer stem cells (CSCs) (Bonnet and Dick, 1997), a small selected population within a tumour, characterised by stem-like genomic and epigenetic signatures, including for instance OCT3/4 and NANOG expression. It is still unclear where CSCs originate, but reprogramming and carcinogenesis share many common features. For instance, deactivation of the antitumour p53-p21 barrier increases the yield of iPSC generation (Hong et al., 2009) . For the therapeutic use of stem cells in the future, it is of crucial importance to discriminate between normal and cancer stem cells; however, proper cellular models are still missing. 
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In the present work, we generated two reprogrammed cell lines from human dermal fi broblasts. The fi rst line, CHiPS W, had a differentiation potential comparable to a normal human ESC line while the other, CHiPS A, failed to undergo in vitro and in vivo differentiation and induced germ cell-like tumours, confi rmed by marker expression analysis. We sought to characterise genomic variations at the genome-wide level and to associate these with the behaviour of the cell lines used in this study. G-banding was used to assess variations at the macroscopic level and, subsequently, Affymetrix SNP6.0 arrays were run to detect copy number variations (CNVs) at kb resolution. On this scale, no variations were detected that could be associated with tumour suppressor or oncogenes. Although a number of common structural variants, like InDels or short inversions, escape the methods used in this study, CNVs represent the predominant form of variation, and have the highest de novo mutation rate in the genome. Our results suggest that the role of genomic variations in determining the tumourigenic phenotype might not be a major one, which implies epigenetic-level mechanisms leading to tumourigenic characteristics. However, considering multiple reports of iPSCs genomic instability (Gore et al., 2011; Hussein et al., 2011; Laurent et al., 2011; Mayshar et al., 2010; Pasi et al., 2011) , it remains an open question whether the genomes of the derived cell lines remain stable over time.
The p53 tumour suppressor plays a pivotal role in cancer prevention (reviewed in Molchadsky et al., 2010) but also, as recently demonstrated, in reprogramming somatic cells to pluripotency (Hong et al., 2009; Kawamura et al., 2009; Utikal et al., 2009) . Recent microRNA profi ling analysis of iPSCs and cancer cell lines also demonstrated differences in the status of the p53 network in these two cellular populations (Neveu et al., 2010) . Morigucchi et al. have proposed that a higher ratio of p53 to p21 might be responsible for shifting the balance from stemness to tumourigenicity in iPSCs (Moriguchi et WDR63  ZDHHC11  WDR63  MCOLN3  BRD9  MCOLN3  SYDE2  FAM115A  SYDE2  GJA5  OR2F2  GJA5  GJA8  OR2F1  GJA8  GPR89B  OR2Q1P  GPR89B  NR5A2  PAOX  NR5A2  FAM58B  PCDH11X  FAM58B  GATA2  GATA2  OR11H12  C3orf27  NF1L6  RPN1  NF1L4  TMED10P2  TMPRSS15  MIR720  PPIAL3  UGT2B28  EFCAB6  RBPJP6  SULT4A1  ATP5A1P6  PNPLA5  MTG1  HMGN2L9  CYP2E1  SPRN  STX2  RAN  NF1L6  NF1L4  TMPRSS15  PPIAL3  EFCAB6  SULT4A1  PNPLA5  HMGN2L9  ZNF81   ZNF182   ZNF630   SPACA5   Table 2 . List of the genes in the affected regions characteristic for a given line.
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Moriguchi, as the ratio of p53 to p21 was lower in the tumourigenic CHiPS A line than in the CHiPS W line. The lack of differentiation within the CHiPS A-derived teratomas resembles tumours derived with p53-defi cient iPSCs, using the four Yamanaka factors (Hong et al., 2009) . Accordingly, we observed lower p53 protein expression in our tumourigenic line CHiPS A, compared to the CHiPS W. This is in accordance with the crucial role of p53 in limiting tumourigenicity. At the same time, the p53/p21 ratio in the CHiPS 22 line, contrary to the CHiPS A, was similar to the CHiPS W, suggesting that other mechanisms are involved (data not shown). At this stage of investigation, we can only speculate on the possible molecular mechanism leading to the observed phenotype. Reprogramming of somatic cells into the CHiPS A and CHiPS W lines was achieved by initial pretransduction with NANOG. A recent report by Tiemann et al. shows the importance of the stoichiometry of RGs in the reprogramming process (Tiemann et al., 2011) . It remains to be determined if the pre-selection with puromycin in the CHiPS W line signifi cantly changed the fi nal stoichiometry of the RGs, allowing better reprogramming into a stable pluripotent state as compared to the CHiPS A and CHiPS22 lines. Considering the Tiemann et al. data, it is plausible that a distinct stoichiometry of RGs controls not only full reprogramming, but also the balance between the pluripotent and tumourigenic phenotypes.
Although NANOG is not considered to be cancer inducing, it might have pre-induced the cell to additional (Lindgren et al., 2011) . In germ cell tumours and derived cell lines, methylation of CpGs in the NANOG promoter has been correlated with the differentiation state (Nettersheim et al., 2011) . Consequently, the lack of silencing of endogenous and/or exogenous NANOG expression during the CHiPS A and the CHiPS 22 differentiation in vitro and in the tumours might be directly responsible for the observed phenotype. Whether pre-induction of fi broblasts with NANOG carried by excisable factors or other transient means would result in the same cellular phenotype remains to be determined. We believe that the resulting phenotype is an outcome of complex and interrelated epigenetic changes. The role of NANOG seems to be crucial; however, CHiPS A and CHiPS 22 differ despite their similar phenotypes. For instance, the CHiPS A line lacks SOX2 expression. Nevertheless the re-introduction of SOX2 using a lentiviral vector did not rescue the phenotype and the new SOX2+ / CHiPS A line still failed to differentiate (data not shown). Furthermore, the tumourigenic CHiPS 22 line expresses SOX2, which altogether suggests that the molecular mechanism is not SOX2-dependent. Similarly, the CHiPS A line, in contrast to the CHiPS 22, overexpresses OCT3/4 and, as previously demonstrated, ectopic expression of OCT3/4 might block progenitor differentiation and cause carcinogenesis (Hochedlinger et al., 2005) . Likewise, human cancers often display altered expression of MYC, a proto-oncogene used here during the reprogramming of the CHiPS 22 line. It has also been demonstrated during reprogramming that the MYC oncogene leads to increased tumour transformation (Okita et al., 2007) . However, the CHiPS A was reprogrammed with the Thomson set of reprogramming genes, and its MYC expression was barely stimulated (data not shown), indicating that MYC is not directly responsible for the resulting carcinogenic behaviour.
Conclusion and Summary
The present data highlight fi ve major points: priming with NANOG before reprogramming of human somatic cells can generate cells with the characteristics of iPS cells; despite their expression of pluripotency markers, such cell lines may fail to differentiate; in vitro differentiation failure might translate into germ cell-like tumour induction in the in vivo differentiation assay; the tumourigenic iPSC line might be genetically stable which implicates the involvement of epigenetic mechanisms in the activation of the carcinogenic program; one of the plausible mechanisms of carcinogenic program induction may involve the p21/ p53 ratio.
Our results are the fi rst describing iPSC lines that behave similarly to pluripotent cell lines in vitro but are unable to differentiate. These cells do however induce germ cell-like tumours in vivo. The tumourigenic character of the reprogrammed lines might result from epigenetic events that occurred during priming the cells with NANOG. It is therefore important to test derived iPSCs, not only at the molecular and cellular level, but also using an in vivo teratoma formation assay, which is essential in the assessment of the carcinogenic potential of the reprogrammed pluripotent stem cells. At the same time, we believe that our results might open new vistas in the area of stemness versus carcinogenesis, while the CHiPS A, CHiPS 22 and CHiPS W lines might serve as a model for comparing cellular signalling leading to normal and malignant conditions.
